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Invasive punch or incisional skin biopsy specimens are currently employed for the bacteriological conﬁr-
mation of the clinical diagnosis of Buruli ulcer (BU), a cutaneous infectious disease caused by Mycobacterium
ulcerans. The efﬁcacy of ﬁne-needle aspirates (FNA) using ﬁne-gauge needles (23G by 25 mm) for the laboratory
conﬁrmation of BU was compared with that of skin tissue fragments obtained in parallel by excision or punch
biopsy. In three BU treatment centers in Benin, both types of diagnostic material were obtained from 33
clinically suspected cases of BU and subjected to the same laboratory analyses: i.e., direct smear examination,
IS2404 PCR, and in vitro culture. Twenty-three patients, demonstrating 17 ulcerative and 6 nonulcerative
lesions, were positive by at least two tests and were therefore conﬁrmed to have active BU. A total of 68
aspirates and 68 parallel tissue specimens were available from these conﬁrmed patients. When comparing the
sensitivities of the three conﬁrmation tests between FNA and tissue specimens, the latter yielded more positive
results, but only for PCR was this signiﬁcant. When only nonulcerative BU lesions were considered, however,
the sensitivities of the conﬁrmation tests using FNA and tissue specimens were not signiﬁcantly different. Our
results show that the minimally invasive FNA technique offers enough sensitivity to be used for the diagnosis
of BU in nonulcerative lesions.
Mycobacterium ulcerans disease, or Buruli ulcer (BU), a dev-
astating skin disease that may affect bone, is the third most
common mycobacteriosis after tuberculosis and leprosy. The
disease is focally endemic in Africa, the Americas, Australia,
and Asia, where rural populations are the most affected (14,
28, 32).
For many years, the standard treatment of BU was surgical
excision of affected tissue (1, 29). Now, however, speciﬁc an-
tibiotic therapy for 8 weeks without surgery has been increas-
ingly implemented, especially in patients with small lesions,
whether closed or ulcerative (6, 9, 31). This recent develop-
ment increases the importance of conﬁrming the clinical diag-
nosis of BU by laboratory techniques to avoid therapy with
antimycobacterial drugs when the lesion is not caused by M.
ulcerans (30). However, with the decreasing importance of
surgery as a therapeutic intervention, tissues for microbiolog-
ical diagnosis are often not available. Alternatively, punch bi-
opsy specimens, requiring local anesthesia, have been em-
ployed for conﬁrmation of the clinical diagnosis of BU (23).
In fact, while microbiological tests on ulcerative forms of BU
can be performed on multiple swabs of exudates taken from
the undermined edges of ulcers, for nonulcerative forms the
microbiological diagnosis must be carried out on tissue frag-
ments, i.e., collected by incisional or punch biopsy (30). As a
minimal invasive technique, ﬁne-needle aspiration (FNA),
commonly used for the cytologic diagnosis of tumors (10, 11),
lymphadenopathies caused by trypanosomiasis (17) and tuber-
culosis (8, 15, 27), leprous osteitis (20), or leprotic neuritis
(16), would seem to offer an advantageous alternative.
In addition, FNA could be valuable for the follow-up of the
infection, during and after treatment with antimycobacterial
drugs. Compared to punch biopsy specimens, FNA includes
less risk of ulceration or possible subsequent reactivation of
healing lesions since it is a minimally invasive procedure. Very
recently, Phillips et al. (24) also reported the use of FNA for
the diagnosis of BU.
In three BU treatment centers in Benin (Centres de De´p-
istage et de Traitement de l’Ulce`re de Buruli [CDTUB] at
Zagnanado, Allada, and Lalo), FNA was applied to clinically
suspected cases of BU. The efﬁcacy of this technique, as a
source of diagnostic material, was compared in parallel with
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that of tissue fragments obtained by excision or punch biopsy,
concerning the laboratory conﬁrmation of both ulcerative and
nonulcerative BU lesions.
MATERIALS AND METHODS
Collection of specimens in Benin. Sampling was carried out in November 2006.
During anesthesia and before surgery, 84 FNA samples were taken from lesions
of 33 consecutively enrolled patients with a clinical diagnosis of BU. Sampling
was carried out by the same study physician (Y.B.) in all BU treatment centers.
Patients were under treatment for various periods of time (see Table 3) with
streptomycin and rifampin combined with surgery (31). Depending on the size of
the lesion, up to six aspirates were taken from each lesion using ﬁne-gauge
needles (23G by 25 mm) attached to 10-ml syringes. An optimal aspiration
technique is very important to obtain sufﬁcient material (12). The needle is
advanced through the skin without applying suction. For nonulcerative forms,
the middle of the lesion is sampled; for ulcerative forms, the undermined edges
are sampled (30). Suction is applied while moving the needle back and forth
repeatedly through the lesion in multiple directions. Aspiration is terminated
when ﬂuid ﬁrst appears at the needle hub. With cessation of aspiration and with
the needle still inside the skin, negative pressure within the syringe returns the
syringe piston to the base of the syringe barrel automatically. The reason for
releasing suction before the needle is withdrawn is to leave the maximum amount
of aspirated material inside the needle. This is so because if the needle is
withdrawn from the lesion under negative pressure in the syringe, the aspirated
specimen is drawn into the syringe and is dispersed into numerous small droplets.
These droplets would stick to the walls of the syringe barrel and would be
virtually impossible to recover (10). After withdrawal from the lesion, the needle
is detached from the syringe, and the syringe is allowed to ﬁll with air. The needle
is then placed back onto the syringe, uncovered, and the specimen is dispersed
into the transport medium.
Aspirates were stored at 4°C in a liquid transport medium (LTM) containing
Middlebrook 7H9 broth supplemented with polymyxin B, amphotericin B, nali-
dixic acid, trimethoprim, and azlocillin (PANTA, Becton Dickinson, Sparks,
MD) and OADC (oleic acid, albumin, dextrose, and catalase) (Difco Laborato-
ries, Detroit, MI). The needle was detached from the syringe, and the content of
the needle hub was smeared on a slide for direct smear examination (DSE).
During surgery, parallel tissues were removed at the same sites from which the
aspirates were taken. In the CDTUB of Zagnanado, fragments of 1 g from
surgically excised tissues were taken, while in the CDTUB of Allada and Lalo,
4-mm punch biopsy specimens were used. Tissue specimens were stored at 4°C
in a sterile vial with 1 ml of a semisolid transport medium with the same
components as LTM plus 0.5% agar. This medium is efﬁcient for storage of
clinical specimens from patients with BU (7).
All specimens were transported to Belgium at ambient temperature and pro-
cessed within 2 weeks.
Microbiological analysis of specimens in Belgium. Smears prepared in Benin
were stained with auramine and read using ﬂuorescence microscopy according to
the American Thoracic Society scale (4). The LTM containing the aspirate was
processed for IS2404 PCR (13) and in vitro culture after decontamination using
the reversed Petroff technique (22).
Tissue fragments were cut into small pieces, ground aseptically with a mortar
and pestle, and suspended in 2 ml phosphate-buffered saline as previously de-
scribed (30). One drop of this suspension was dried on a slide, stained with
auramine, and read using ﬂuorescence microscopy. IS2404 PCR and in vitro
culture were performed on the suspensions.
When culture tubes of specimens with positive results by PCR and DSE were
contaminated by other microorganisms, the specimens were processed again for
in vitro culture after decontamination with oxalic acid as previously described by
Portaels et al. (25) and Yeboah-Manu et al. (33). Brieﬂy, 0.5 ml of 0.2% mala-
chite green, 0.5 ml NaOH, and 0.1 ml of 0.8% actidione were added to 0.5 ml of
the specimen suspended in phosphate-buffered saline. This mixture was left for
30 min at room temperature and then centrifuged for 15 min at 3,500  g. The
supernatant was discarded, and 1 ml of 5% oxalic acid was added to the sediment
and left at room temperature for 20 min. The suspension was then centrifuged
again for 15 min at 3,500  g, after which 0.1 ml of the pellet, suspended in 1 ml
distilled water, was inoculated onto Lo¨wenstein-Jensen medium, incubated at
30°C, and examined weekly for growth. Positive cultures were identiﬁed to the
species level based on phenotypic characteristics (18).
Statistical analysis. Data were analyzed statistically with Epi Info v. 3.3.2 and
SPSS v. 16.0. Pearson’s chi-square test was used to compare proportions, and
Student’s t test was applied to compare means of symmetric distributions. Sen-
sitivities were calculated as the ratio of positives for a certain test to the total
number of specimens from conﬁrmed patients.
Ethical provisions. This study had the agreement of the Ministry of Health of
Benin. All patients (or their parents or guardians, for children younger than 15
years) gave their oral informed consent to participate in the study.
RESULTS
Among the 33 patients, 23 were conﬁrmed to have active BU
according to WHO guidelines (30): at least two positive tests
among the DSE, PCR, and culture methods (Table 1). Six
patients did not have BU, and four were found to have inactive
BU (only one positive test by either DSE or PCR). Among the
23 conﬁrmed BU patients, 17 had ulcers and 6 had nonulcer-
ative lesions: plaques (3), edema (2), or osteomyelitis (1).
When classiﬁed according to WHO guidelines (31), 3 patients
had early lesions (category I), 17 had large lesions (category
II), and 3 had disseminated lesions (category III) (Table 1).
Altogether 68 aspirates and 68 parallel tissue specimens were
available from these conﬁrmed patients.
DSE. Sensitivity of DSE by FNA was 32.4% (22/68) (Table
2). This is not signiﬁcantly lower than the sensitivity on tissue
specimens, which was 38.2% (26/68) (P  0.59). A comparison
of the sensitivities of DSE by FNA of ulcerative and nonulcer-
ative lesions revealed that nonulcerative lesions were signiﬁ-
cantly more often positive for acid-fast bacilli (AFB) than
ulcerative lesions (64.7% versus 21.6%; P  0.003). In tissue
specimens, the sensitivity of DSE was also higher for nonul-
cerative lesions, but this was not signiﬁcant (P  0.08). The
sensitivity of DSE was higher by FNA than on tissue specimens
from nonulcerative lesions, but this was not statistically signif-
icant (64.7% versus 58.8%; P  0.70).
IS2404 PCR. In general, the sensitivity of PCR for the total
number of FNA specimens was 48.5% (33/68) (Table 2). This
is signiﬁcantly lower than the sensitivity for tissue specimens,
which was 85.3% (58/68) (P  0.0001). When comparing the
sensitivities of PCR on FNA of ulcerative and nonulcerative
TABLE 1. Treating CDTUB, categorization according to WHO,
clinical presentation, and type of specimen with at least







a Conﬁrmation No. ofspecimens
06-213 Zagnanado I U FNA, tissue 3
L06-217 Lalo I U FNA, tissue 1
L06-220 Lalo I U FNA 2
06-182 Zagnanado II U Tissue 2
06-196 Zagnanado II U FNA, tissue 3
06-212 Zagnanado II U FNA, tissue 6
06-214 Zagnanado II NU FNA, tissue 2
06-216 Zagnanado II U Tissue 1
06-223 Zagnanado II NU FNA, tissue 6
A239/10/6 Allada II U Tissue 4
A252/10/6 Allada II U FNA, tissue 3
A365/11/6 Allada II U FNA, tissue 2
A366/11/6 Allada II NU FNA, tissue 2
A369/11/6 Allada II U FNA, tissue 4
A375/11/6 Allada II NU FNA, tissue 2
A378/11/6 Allada II U Tissue 3
A379/11/6 Allada II U FNA, tissue 3
L06-117 Lalo II U Tissue 4
L06-195 Lalo II NU FNA, tissue 2
L06-213 Lalo II U Tissue 1
04-36 Zagnanado III U Tissue 5
06-186 Zagnanado III U FNA, tissue 4
06-221 Zagnanado III NU FNA, tissue 3
a U, ulcerative lesion; NU, nonulcerative lesion.












lesions, signiﬁcantly more PCR-positive samples were found in
nonulcerative lesions (88.2% versus 35.3%; P  0.001). In
tissue specimens, the sensitivities of PCR for ulcerative and
nonulcerative lesions were not signiﬁcantly different (P 
1.00). For nonulcerated lesions alone, the sensitivities of PCR
on FNA and tissue specimens were identical (88.2%).
In vitro culture. The sensitivity of in vitro culture with FNA
specimens was 17.6% (12/68) (Table 2). This is not signiﬁcantly
lower than the sensitivity on tissue specimens, which was 25.0%
(17/68) (P 0.40). When comparing the sensitivities of in vitro
culture of FNA of ulcerative and nonulcerative lesions, the
latter were signiﬁcantly more often positive (9.8% versus
41.2%; P  0.007). Also in tissue specimens, nonulcerative
lesions yielded more positive cultures (P  0.001). The sensi-
tivities of in vitro culture in nonulcerative lesions with FNA
and tissue specimens were not signiﬁcantly different (41.2%
versus 58.8%; P  0.30).
Inﬂuence of chemotherapy on positivity of bacteriological
tests. In specimens from patients under treatment, DSE and
PCR remained positive, although a decrease in positivity was
observed both for FNA and tissue specimens (Table 3). In
contrast, FNA and tissue specimens from patients under treat-
ment for 4 weeks or more did not yield any positive cultures.
DISCUSSION
The ﬁrst attempt to conﬁrm BU diagnosis by puncturing a
lesion with a needle was made in 1957 in the Democratic
Republic of Congo on an extensive edematous lesion of the
arm. A smear of the exudate stained by the Ziehl-Neelsen
method revealed AFB (14).
In a study by Singh et al. (27), the sensitivity of laboratory
tests for the conﬁrmation of tuberculous lymphadenitis was
higher with biopsy specimens than with FNA material. In our
study, when the sensitivities of laboratory tests obtained for the
total number of FNA and tissue specimens (regardless of clin-
ical form) were compared, tissue specimens yielded more pos-
itive results—but only by PCR, the most sensitive test. Impor-
tantly, when considering only nonulcerative BU lesions, the
sensitivities obtained from FNA and tissue specimens were not
signiﬁcantly different by PCR or by any of the other conﬁrma-
tory tests (Table 2). These results emphasize the potential of
FNA for conﬁrmation of the diagnosis of nonulcerative forms
of BU since ulcers can easily be conﬁrmed on swabs. With
nonulcerative forms of BU, however, an invasive sampling
technique is currently necessary, and FNA is a much less trau-
matic approach.
In the present study, three bacteriological conﬁrmation tests
were performed and PCR was found to be the most sensitive
technique, for both FNA and tissue specimens, for ulcerative
as well as for nonulcerative lesions (Table 2). The second most
sensitive conﬁrmation test was DSE, followed by in vitro cul-
ture. Comparable observations have been reported in other
studies (5, 7, 23). These ﬁndings are analogous to those re-
ported for the use of FNA for the diagnosis of tuberculous
lymphadenitis (2, 8, 15, 27). Also, a recent study by Phillips et
al. (24) reports PCR as the most sensitive technique for con-
ﬁrming the presence of M. ulcerans in FNA of nonulcerative
BU lesions.
In the present study, FNA samples from nonulcerative le-
sions had signiﬁcantly higher positivity rates than FNA samples
from ulcerative lesions for all of the tested laboratory methods.
This may be due to the sampling technique, since in ulcerative
lesions it is probably more difﬁcult to ﬁnd the most productive
sampling site. In the ulcerative lesions that have not been
debrided, the necrotic slough in the base of the ulcer contains
the majority of AFB. After debridement, the largest numbers
of AFB are seen at the base of the ulcer in the undermined
TABLE 2. Results from DSE, PCR, and in vitro culture of FNA and tissue specimens of ulcerative and nonulcerative BU lesions
Parameter









(6 patients) Total (23 patients)
DSE positive 16 (31.4) 10 (58.8) 26 (38.2) 11 (21.6)* 11 (64.7)* 22 (32.4)
PCR positive 43 (84.3) 15 (88.2) 58 (85.3)† 18 (35.3)† 15 (88.2)† 33 (48.5)†
Culture positive 7 (13.7)§ 10 (58.8)§ 17 (25.0) 5 (9.8)¶ 7 (41.2)¶ 12 (17.6)
Total no. of specimens 51 17 68 51 17 68
a Statistically signiﬁcant differences between the results of the analyses as evaluated by Pearson chi-square test are indicated as follows for the values compared: *,
P  0.003; †, P  0.0001; †, P  0.0005; §, P  0.0006; and ¶, P  0.007.
TABLE 3. Results of DSE, PCR, and in vitro culture of FNA and




No. (%) of patients positive during
chemotherapy at:
wk 0 wk 1–3 wk 4–6
DSE
FNA 2 (100.0) 6 (42.9) 2 (40.0)
Tissue 2 (100.0) 8 (57.1) 2 (40.0)
PCR
FNA 2 (100.0) 9 (64.3) 3 (60.0)
Tissue 2 (100.0) 14 (100.0) 3 (60.0)
Culture
FNA 2 (100.0) 4 (28.6) 0 (0)
Tissue 2 (100.0) 7 (50.0) 0 (0)
Total no. of patients 2 14 5












edges. Using tissue fragments in a larger study, we have also
observed a higher positivity rate in the conﬁrmation tests for
nonulcerative lesions (plaques and edemas) than for ulcerative
lesions (F. Portaels et al., unpublished data). Positivity of mi-
crobiological conﬁrmation tests also varies in tuberculous
lymphadenitis, depending on the type of lesion (19, 21).
Recent unpublished studies by our group of more than 1,000
BU patients show that at least two tissue specimens from the
same lesion must be analyzed to achieve acceptable sensitivity
for the bacteriological conﬁrmation of BU (F. Portaels, unpub-
lished data). The taking of multiple FNA aspirations from
different sites of the lesion may thus be justiﬁed to increase the
sensitivity of the laboratory tests. In the present study, patients
were anesthetized before the sampling procedures because
these preceded surgery. FNA is routinely used for cytologic
diagnoses without anesthesia (12). The pain when taking ﬁve
to seven FNA in breast lesions of 79 patients has been reported
to be 3.19 on a scale of 0 (no pain) to 10 (worst possible pain)
(34). It is therefore expected that for sampling of diagnostic
FNA specimens from BU lesions, anesthesia would also not be
necessary.
In both FNA and tissue specimens, DSE and PCR remained
positive during treatment (Table 3). This type of phenomenon
has been observed in patients with tuberculosis, whose sputum
smears may remain positive for AFB after up to 36 weeks of
treatment while cultures became negative much earlier (3).
Moreover, the overall sensitivities of in vitro culture with FNA
as well as tissue specimens were lower in this study than those
in previous studies (7, 23). The reason for this is probably that
most of the patients included in this study were undergoing
treatment when the specimens were collected, therefore reduc-
ing the number of viable bacilli in the lesion. Thus, this study
also demonstrates the importance of FNA for follow-up of
chemotherapy when the use of more invasive sampling tech-
niques could be deemed unethical. Indeed, according to our
observations, the outcome of in vitro culture from nonulcer-
ative BU lesions could be best assessed in FNA specimens.
We have evaluated several small collections of FNA speci-
mens taken by other teams of investigators who used 19G
needles and found them much less productive in the conﬁrma-
tion of BU (data not shown). The types of lesions sampled and
the techniques employed were not uniform; however, direct
comparisons of samples taken by 19G and 23G needles seem
warranted.
Siegmund et al. (26) found a great variation in positivity
rates of bacteriological tests between BU treatment centers,
suggesting that the quality of the clinical diagnosis and of
sampling specimens differed between centers. We therefore
recommend the development of training sessions on the dif-
ferent sampling techniques for the conﬁrmation of BU: tissue
or swab specimens from ulcerative lesions and FNA from non-
ulcerative lesions.
In conclusion, our results support the use of FNA, a mini-
mally invasive technique, as a sensitive sampling method for
the diagnosis and follow-up of BU in nonulcerative lesions.
The facts that the available sampling techniques for conﬁrma-
tion of BU diagnosis cause high levels of discomfort and that
BU affects primarily children reinforce the need to develop less
invasive sampling methods as proposed here. Additionally, due
to the present sampling difﬁculties, antibiotic treatment is of-
ten performed without bacteriological conﬁrmation of BU,
implying the risk of submitting patients to long chemothera-
peutic protocols in skin lesions not caused by M. ulcerans.
Moreover, in these cases, conﬁrmation of BU diagnosis may
prevent potentially harmful surgery. Our ﬁndings have there-
fore a potential impact in beneﬁt of patients with nonulcerative
lesions. However, studies in larger case series of patients with
nonulcerative lesions are warranted before making any recom-
mendations to replace the more invasive techniques currently
used for the diagnosis of BU. In addition, further studies are
needed to optimize the sensitivity of BU conﬁrmation tests on
FNA taken with needles of different sizes and on the number
of FNA aspirates that would be ideal to obtain an optimal
sensitivity for the laboratory conﬁrmation of BU diagnosis.
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